Abstract How parathyroid hormone (PTH) increases bone mass is unclear, but understanding this phenomenon is significant to the improvement of osteoporosis therapy. Nmp4/ CIZ is a nucleocytoplasmic shuttling transcriptional repressor that suppresses PTH-induced osteoblast gene expression and hormone-stimulated gains in murine femoral trabecular bone. To further characterize Nmp4/CIZ suppression of hormonemediated bone growth, we treated 10-week-old Nmp4-knockout (KO) and wild-type (WT) mice with intermittent human PTH(1-34) at 30 lg/kg daily or vehicle, 7 days/week, for 2, 3, or 7 weeks. Null mice treated with hormone (7 weeks) gained more vertebral and tibial cancellous bone than WT animals, paralleling the exaggerated response in the femur. Interestingly, Nmp4/CIZ suppression of this hormonestimulated bone formation was not apparent during the first 2 weeks of treatment. Consistent with the null mice enhanced PTH-stimulated addition of trabecular bone, these animals exhibited an augmented hormone-induced increase in serum osteocalcin 3 weeks into treatment. Unexpectedly, the Nmp4-KO mice displayed an osteoclast phenotype. Serum C-terminal telopeptide, a marker for bone resorption, was elevated in the null mice, irrespective of treatment. Nmp4-KO bone marrow cultures produced more osteoclasts, which exhibited elevated resorbing activity, compared to WT cultures. The expression of several genes critical to the development of both osteoblasts and osteoclasts was elevated in Nmp4-KO mice at 2 weeks, but not 3 weeks, of hormone exposure. We propose that Nmp4/CIZ dampens PTH-induced improvement of trabecular bone throughout the skeleton by transiently suppressing hormone-stimulated increases in the expression of proteins key to the required enhanced activity and number of both osteoblasts and osteoclasts.
Data on the self-limiting pathways to PTH action, inherent to all endocrine response loops, are lacking; and it is these molecules that may provide the best pharmaceutical targets for improving hormone efficacy and cost-effectiveness [3] . For example, as PTH activates the osteoblast generation of cAMP and the enhanced expression of RUNX2, it simultaneously stimulates phosphodiesterase activity [4] and Smurf1-mediated RUNX2 proteasomal degradation [5] .
We recently demonstrated that disabling the nucleocytoplasmic shuttling transcription factor Nmp4/CIZ (nuclear matrix protein 4/cas interacting zinc finger protein) in mice enhances the skeletal response to anabolic PTH [6] , suggestive of a significant role in the hormone's self-limiting pathways. Ten-week-old Nmp4-knockout (KO) mice treated with intermittent PTH for 7 weeks exhibited an augmented increase in femoral trabecular bone compared to wild-type (WT) mice without compromising the hormonestimulated increases in bone mineral density (BMD) and content throughout the skeleton [6] .
The ubiquitously expressed Nmp4/CIZ appears to act as a general repressor of anabolic bone growth, in part, by suppressing the transcription of genes that support the development of the osteoblast phenotype, including the pro-alpha1(I) chain (Col1a1) and the Mmp-13 promoters [3, 7, 8] . This trans-acting protein suppressed the PTH induction of rat Mmp-13 transcription in UMR-106-01 osteoblast-like cells via its binding to a PTH-responsive element in the 5 0 regulatory region of the gene [8] , but whether Nmp4 represses the hormone responsiveness of other tissues has not been reported.
In the present study we determined that Nmp4/CIZ suppressed the PTH-stimulated improvement of trabecular bone throughout the mouse skeleton and was not sitespecific, as is common in other mouse models [9, 10] . Most surprisingly, we discovered that the null mice have an osteoclast phenotype. Analysis of serum biochemistry, bone histomorphometry, bone mRNA expression profiles, and osteoclast cell culture suggested that the numbers and activities of both osteoblasts and osteoclasts are enhanced in Nmp4-KO mice due, in part, to a transient derepression of key transcription factors and signaling proteins common to pathways critical for the development and hormone responsiveness of both cell types.
Materials and Methods

Mice
Construction of the Nmp4-KO mouse, its backcrossing six generations onto a C57BL/6J background, and the baseline phenotype have been described [6] . As in our previous study, WT C57BL/6J mice from Jackson Laboratories (Bar Harbor, ME) were used as controls [6] . Experiments designed to compare the response of WT and Nmp4-KO mice to PTH compensated for any differences in genetic and environmental factors (see Statistical Analyses). Our local Institutional Animal Care and Use Committee approved all experiments and procedures involving the production and use of the experimental mice described in this study.
PTH Treatment Regimen
Prior to the start of an experiment, 8-week-old female WT and Nmp4-KO mice were given 100 ll sterile saline by subcutaneous (sc) injection once daily to acclimatize them to handling. At 10 weeks of age, mice were sorted into four groups based on equivalent mean group body weight. The four treatment groups were (1) vehicle-treated WT, (2) PTH-treated WT, (3) vehicle-treated Nmp4-KO, and (4) PTH-treated Nmp4-KO. Mice were injected sc with human PTH(1-34) (Bachem Bioscience, Torrance, CA) at 30 lg/kg daily or vehicle control (0.2% BSA/0.1% 1.0 mN HCl in saline; Abbott Laboratory, North Chicago, IL) for the times specified (see Results). Additionally, animals were administered intraperitoneal injections of calcein green (20 mg/kg; Sigma-Aldrich, St. Louis, MO) and alizarin red (25 mg/kg, Sigma-Aldrich) 6 and 3 days before being killed, respectively.
Dual-Energy X-Ray Absorptiometry
Bone mineral content (BMC, g), areal bone mineral density (aBMD, mg/cm 2 ), and body weight were measured weekly (8-12 weeks of age). BMC and aBMD were obtained for the postcranial skeleton by dual-energy X-ray absorptiometry (DEXA) using an X-ray PIXImus mouse densitometer (PIXImus II; GE-Lunar, Madison, WI) as previously described [6] . We report whole-body (WB), femur, tibia, and spine BMD and BMC.
Micro-Computed Tomography
Vertebrae, femora, and tibiae were dissected from WT and Nmp4-KO animals after death; the connective tissue and muscle were removed; and the bones were stored in 10% buffered formalin at 4°C. After 48 h, the bones were transferred to 70% ethanol and stored at 4°C until analyzed. We previously described our methodology for assessing the trabecular microarchitecture at the distal femoral metaphysis and within the fifth lumbar vertebra using a desktop micro-computed tomographer (lCT 20; Scanco Medical, Bassersdorf, Switzerland) [6, 9] . Cancellous bone of the tibia was evaluated by scanning the proximal 20% of each tibia at 9 lm resolution. A microfocus X-ray tube with a focal spot of 10 lm was used as a source. Precisely 90 lCT slices were acquired per bone beginning 1 mm from the epiphysis and extending distally 1.53 mm using a slice increment of 17 lm. For each slice, 600 projections were taken over 216°(180°plus half of the fan angle on either side). Proximal tibia stacks were reconstructed to the third dimension using a standard convolution-backprojection procedure with a Shepp-Logan filter using a threshold value of 275. The Scanco software permitted evaluation of tibial, femoral, and vertebral trabecular bone volume per total volume (BV/TV), connectivity density (Conn.D, mm -3 ), structure model index (SMI), trabecular number (Tb.N, mm -1 ), trabecular thickness (Tb.Th, mm), and trabecular spacing (Tb.Sp, mm) from the 3D constructs. To evaluate cortical architecture, a single slice was taken through the midshaft femur (simply by measuring the number of slices for the whole femur and dividing by 2), and the cortical area (CA, mm 2 ), marrow area (MA, mm 2 ), and total area (TA, mm 2 ) were calculated [6] . Additionally, the moment of inertia (the resistance of the bone to a bending load) was derived from these data. These parameters included the largest (I MAX , mm 4 ) and smallest (I MIN , mm 4 ) flexural rigidity as well as the polar moment of inertia (J, mm 4 ), which is the torsional and bending rigidity around the neutral axis of the bone and perpendicular to the x and y axes passing through the center of mass [11] .
Quantitative Real-Time PCR Analysis Femoral or tibial RNA from mice that had been treated with intermittent PTH or vehicle for 2 or 3 weeks was harvested either 1 or 24 h after the last injection. The harvesting, processing, and analysis protocols for quantitative real-time PCR analysis have been described [6, 9] . Real-time PCR primers and probes were obtained from Assays-on-Demand TM (Applied Biosystems, Foster City CA; see Table 1 ). The DDCT method was used to evaluate gene expression between WT and KO animals using Rplp2 as the normalizer after screening several housekeeping gene candidates. The coefficient of variation of Rplp2 was Col1a1 (type I; pro-alpha1(I) chain) Mm00801666_g1
EphB4 (ephrin type-B receptor 4) Mm01201157_m1
EphrinB2 (EPH-related receptor tyrosine kinase ligand 5) Mm00438670_m1
Fra-2 (fos-related antigen 2) Mm00484442_m1
Igf-1 (insulin-like growth factor 1) Mm0043559_m1
JunD (Jun proto-oncogene related gene d) Mm00495088_s1
Lef1 (lymphoid enhancer-binding factor-1) Mm00550265_m1
M-csf (macrophage colony stimulating factor 1) Mm00432686_m1
Mcp-1 (monocyte chemotactic protein-1) Mm00441242_m1
Mkp-1 (MAPK phosphatase 1) Mm00457274_g1
Mmp-13 (matrix metalloproteinase 13) Mm00439491_m1
Nfatc1 (nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1) Mm012479445_m1
Nurr-1 (nuclear receptor-related factor 1) Mm00443056_m1
Osterix (Sp7 transcription factor) Mm00504574_m1
Pthr1 (parathyroid hormone receptor 1) Mm00441046_m1
Pthrp (parathyroid hormone-related peptide) Mm00436057_m1
Rage (Ager) (receptor for advanced glycation endproducts) Mm00545815_m1
Rankl (receptor activator for nuclear factor j B ligand) Mm00441908_m1
Runx2 (runt-related transcription factor 2) Mm00501578_m1
Smad3 (Sma-and Mad-related protein) Mm01170760_m1
typically 2-3% between all samples. Normalization against internal control genes is most frequently used because it can control all variables including cell number [12, 13] . The data represent the mean ± standard deviation from at least six mice per genotype.
Bone Histomorphometry
Femora were removed from WT and Nmp4-KO animals after death and fixed as described above. The anterior face of the epiphyseal plate was cut to expose the marrow cavity. Samples were then dehydrated with graded alcohols, embedded in methyl-methacrylate, sectioned (4 lm) with a microtome (RM2255; Leica Microsystems, Wetzlar, Germany), and mounted on standard microscope slides. All histomorphometric parameters were obtained following ASBMR guidelines [14] . 
Serum Biochemistry
Intact serum osteocalcin was measured using the sandwich ELISA BTI Mouse Osteocalcin EIA Kit (Biomedical Technologies, Stoughton MA) [15] . Serum C-terminal telopeptides (CTX) were determined using the RatLaps TM ELISA (Immunodiagnostic Systems, Scottsdale, AZ) [15] .
Osteoclast Culture and Activity
To compare the number of osteoclasts derived from Nmp4-KO and WT mice, bone marrow was flushed from the long bones of animals 6-8 weeks old. Cells were seeded into 24-well culture dishes at an initial density of 2.1 9 10 5 / mm 2 and cultured in alpha-MEM (Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Hyclone, Logan, UT) and 20 ng/ml of recombinant human M-CSF (Peprotech, Rocky Hill, NJ) for 2 days and then supplemented with 20 ng/ml of recombinant human M-CSF and 80 ng/ml of recombinant human RANKL (Peprotech) for the duration of the experiment. The cell culture medium was changed every third day until osteoclasts were visible. Once osteoclasts had formed, the cells were fixed with 2.5% glutaraldehyde in phosphate-buffered saline for 30 min at room temperature and stained for TRAP (Sigma-Aldrich) and TRAP ? , multinucleated (C3) cells were counted.
The osteoclast resorption activity of cells derived from KO and WT mice was evaluated using a standard pit assay [16] . Bone marrow was isolated as above and plated into six-well culture dishes at 2 9 10 6 cells/well (2.1 9 10 5 cells/mm 2 ). As detailed above, cells were incubated in alpha-MEM containing 10% FBS and 20 ng/ml M-CSF for 2 days. The medium was removed and replaced with fresh medium containing 20 ng/ml M-CSF and 80 ng/ml RANKL for an additional 2-3 days. Mature osteoclasts were detached by trypsinization, washed once, replated onto dentin slices (Immunodiagnostic Systems), and cultured for an additional 48 h in medium containing 20 ng/ ml M-CSF and 80 ng/ml RANKL. Dentin slices were washed, incubated in 6% NaOCl for 5 min, and sonicated for 20 s to remove cells. Resorption pits were stained with a solution containing 1% toluidine blue and 1% sodium borate for 1 min, washed with water, and air-dried. Pit surface area was quantified using ImagePro 7.0 on a Leica DMI4000 with a 109 objective. Results were normalized for osteoclast number, as determined by counting TRAP ? cells containing three or more nuclei. Experiments were performed in triplicate, and results represent average pit area per dentin slice/osteoclast number.
Statistical Analyses
Statistical analysis was processed using JMP version 7.0.1 (SAS Institute, Cary, NC). Experiments designed to compare the response of WT and Nmp4-KO mice to PTH compensated for any differences in genetic and environmental factors; i.e., the fact that WT mice were not bred inhouse was accounted for by our analyses. For example, raw BMD and BMC data were converted to percent change (8-12 weeks of age). Comparing hormone-treated to vehicle-treated within each genotype for all end-point analyses removed baseline differences from those factors and permitted analysis for genotype 9 treatment interactions, i.e., whether WT and Nmp4-KO mice responded differently to hormone for the parameter under consideration. We employed a two-factor ANOVA for these analyses. If a genotype 9 treatment interaction was indicated, the data were analyzed by a Tukey HSD post hoc test to determine significant differences between the experimental groups. For the serum analysis experiment we used a repeated-measures multivariate analysis of variance (MA-NOVA) to evaluate the raw longitudinal serum osteoclast and CTX levels over the 7-week hormone treatment period. Additionally, we converted the serum data to percent change and analyzed with the two-factor ANOVA. The genotype 9 time term for the raw longitudinal serum data is equivalent to the genotype term for the percent change data; i.e., both terms indicate a difference in the rate of either osteocalcin/CTX increase or bone accrual (for the BMD/BMC study) between WT and null mice. For some experiments, unpaired t-tests were employed as indicated. Data are presented as mean ± SD unless otherwise indicated. Statistical significance was taken at P \ 0.05. We previously showed that Nmp4-KO mice exhibited a significantly exaggerated PTH-stimulated increase in femoral trabecular bone compared to WT mice after 7 weeks of hormone challenge [6] ; here, we addressed whether Nmp4/CIZ represses PTH-induced improvement in other parts of the skeleton and if this suppression is evident from the start of the treatment regimen. Animals were treated with intermittent hPTH(1-34) 30 lg/kg daily or vehicle for 7 weeks from 10 weeks of age. Mice were sorted in the four treatment groups, and the cancellous architecture was characterized as described in ''Materials and Methods'' section. The Nmp4-KO L5 vertebra BV/TV exhibited a more robust increase in response to 7 weeks of PTH than the WT BV/TV as demonstrated by a strong treatment effect and significant genotype 9 treatment interaction (Fig. 1a) . The PTH-induced change in vertebral morphology from a rod-like to a plate-like form was more pronounced in the null mice (SMI, Fig. 1c ). Vertebral Tb.Th was significantly enhanced in response to 7 weeks of hormone in null mice but not in WT animals ( Fig. 1e) , whereas PTH had an equivalent impact on Tb.Sp (Fig. 1f) , a consequence of the fact that these parameters do not have a simple reciprocal relationship [14] . PTH had an equivalent impact on Conn.D (Fig. 1b) in the genotypes. Finally, there was a strong genotype effect for all the measured vertebral parameters, consistent with the more robust trabecular architecture in the null mice ( Fig. 1a-f ). Typical lCT scans of L5 vertebra from mice treated with intermittent hormone or vehicle for 7 weeks are shown in Fig. 1g .
Results
Nmp4-KO
To evaluate the early hormone response of the L5 vertebra, we compared bones from WT and Nmp4-KO mice that had been treated with PTH or vehicle for 2 weeks. The L5 vertebra trabecular bone showed no improvement after 2 weeks of hormone in either WT or null animals ( Fig. 1a-f ). However, there was a genotype effect for BV/TV, Conn.D, SMI, and Tb.Th (Fig. 1a-c , e, respectively); thus, the enhanced vertebral trabecular architecture observed in the 17-week-old null mice irrespective of treatment was apparent in these mice at 12 weeks of age.
Nmp4/CIZ also repressed the hormone-induced increase in tibial cancellous bone (Fig. 2) . The PTH-stimulated increase in tibial BV/TV after 7 weeks of hormone was greater in null than WT mice (Fig. 2a) . PTH increased tibial Tb.N in both genotypes but significantly more so in null mice (Fig. 2d) , and the hormone-stimulated change in tibial SMI was more pronounced in null mice (Fig. 2c) . PTH had a comparable positive effect on Conn.D (Fig. 2b) , Tb.Th (Fig. 2e) , and Tb.Sp (Fig. 2f ) in WT and null mice with 7 weeks of treatment. Typical lCT scans of tibiae from mice treated with hormone or vehicle for 7 weeks are shown in Fig. 2g .
To evaluate the early hormone response of the tibia, we compared bones from WT and Nmp4-KO mice that had been treated with PTH or vehicle for 2 weeks. Both genotypes showed equal hormone-induced improvement of tibial BV/TV, Conn.D, SMI, and Tb.Th during the initial 2 weeks of treatment ( Fig. 2a-c, e) . PTH failed to improve Tb.N and Tb.Sp in both WT and null mice during this period of the regimen; however, there was a genotype effect for these two parameters, indicating enhanced aspects of tibial architecture in the null mice at 12 weeks of age (Fig. 2d, f) .
Disabling Nmp4 had no impact on any aspect of the skeletal response to PTH (no genotype 9 treatment interaction) during the first 2 weeks of treatment including femoral cancellous architecture (Table 2) , midshaft cortical architecture (Table 3) , and the percent change in skeletal BMD and BMC (Table 4) . Consistent with Nmp4's repressive action on bone growth [6] , genotype effects were observed for some of these parameters indicative of the modestly enhanced skeletal phenotype of the null animals. Interestingly, the genotype effects for WB BMC and femoral and tibial BMD and BMC (Table 4) indicated that the rate of bone accrual was lower in null mice over the 4-week period of measurement irrespective of treatment.
Enhanced PTH-Stimulated Increase in Femoral Trabecular Bone Observed in Nmp4-KO Mice Occurred After 2 Weeks and Before 7 Weeks of Hormone Exposure Histological sections of the femoral spongiosa prepared for histomorphometry (Fig. 3a) confirmed our previous analysis using lCT [6] that Nmp4-KO mice added more cancellous bone in response to 7 weeks of hormone treatment than WT mice. However, BFR parameters were not different between the null and WT mice at the end of treatment and, in fact, were declining, suggesting that the PTH response was beginning to plateau in both genotypes. MS/ BS (the proportion of bone surface undergoing mineralization) was significantly decreased in both genotype treatment groups, consistent with the declining PTH responsiveness (Table 5 ). Additionally, we did not observe a significant hormone-induced increase in BFR in either of the genotypes at this point in treatment (Table 5) . Nevertheless, PTH equally enhanced MAR in both genotypes at this time point (Table 5) .
Our histomorphometric analysis of mice treated with PTH or vehicle for 7 weeks included the parameters of TRAP ? S/BS and TRAP ? n/BS, which provide an estimate of the size and number of osteoclast precursors and mature osteoclasts normalized to the bone surface. Clearly, anabolic hormone treatment enhanced the absolute number of osteoclasts and the total osteoclast surface over bone in both genotypes as evident from the histological sections (Fig. 3b) ; normalizing these parameters to the bone surface revealed that, although both parameters are elevated in null mice, the differences are not statistically significant (Table 5) . However, there were strong treatment effects; i.e., PTH significantly attenuated the percent bone surface covered by TRAP ? cells and their number/surface (Table 5) . Interestingly, there was a genotype 9 treatment interaction for TRAP ? S/BS, indicating that hormone had a larger impact on the reduction of bone surface covered by osteoclasts in null mice than in WT animals ( Table 5 ).
Nmp4-KO Mice Exhibited Strikingly Different Serum Osteocalcin and CTX Profiles Compared to WT Animals
Whole blood was collected and the serum separated from the mice of the four treatment groups at 10 weeks of age (before initiation of treatment), 13 weeks of age (3 weeks of PTH/vehicle treatment), and 17 weeks of age (7 weeks of PTH/vehicle treatment). The raw longitudinal data and the percent change data for osteocalcin, a standard marker for bone formation and osteoblast number, revealed that null and WT mice had equivalent serum levels just prior to hormone treatment but that the Nmp4-KO mice exhibited a higher rate of increase over the hormone treatment period (genotype 9 time interaction, longitudinal data; genotype interaction, percent change data) and an enhanced response to hormone (genotype 9 treatment interaction, Fig. 4a, b) . Specifically, null mice showed an enhanced and sustained increase in osteocalcin after 3 weeks of treatment, while WT animals showed a peak at 3 weeks of treatment, followed by a decline by 7 weeks of treatment (Fig. 4a, b) .
CTX, a marker for bone resorption, was significantly elevated in Nmp4-KO mice compared to WT animals before and during the hormone treatment period. CTX was elevated with PTH treatment in both genotypes, but this increase was not statistically significant (Fig. 4c, d ).
Bone Marrow from
To confirm our serum data indicating increased activity of osteoclasts in Nmp4-KO mice, we compared the number of these cells derived from bone marrow cultures of untreated null and WT animals at 7-8 weeks of age. Bone marrow preparations from three null mice and four WT mice were cultured in six-well plates and treated with M-CSF and RANKL as described in ''Materials and Methods'' section. On average, the Nmp4-KO bone marrow cultures produced twofold more osteoclasts than the WT marrow (null = 1,608 ± 87 osteoclasts/well, WT = 877 ± 243 osteoclasts/ well; P \ 0.05, data presented as average ± SD). This experiment was performed twice, yielding similar results.
Next, we compared the dentin-resorbing activities of Nmp4-KO and WT osteoclasts. Mature osteoclasts were obtained from the bone marrow of WT and null mice (n = 2-3 mice per group) as described in ''Materials and Methods'' section. Fully differentiated bone marrowderived osteoclasts were replated on dentin slices for 48 h. The area resorbed was quantified and normalized for TRAP ? osteoclasts. Nmp4-KO osteoclasts exhibited a 50% increase in the area resorbed on dentin compared to WT osteoclasts (null = 154 ± 4.6% area resorbed/Trap ? cells, WT = 100 ± 13.3% area resorbed/Trap ? cells; P \ 0.05, data presented as average ± SD).
Nmp4-KO Mice Exhibit a Transiently Enhanced Basal or PTH-Stimulated Expression of Genes Common to Osteoblast and Osteoclast Development
To follow up on our observation that both osteoblast and osteoclast numbers were enhanced in null mice, we analyzed femoral RNA harvested during the early phase of PTH treatment to evaluate the expression of genes that ), e Tb.Th (mm), and f Tb.Sp (mm) was compared between WT and Nmp4-KO mice that had been treated with intermittent hPTH(1-34) 30 lg/kg daily or vehicle for 7 weeks (number of mice/experimental group = 11-12). To evaluate the early hormone response, we compared bones from WT and Nmp4-KO mice that had been treated with intermittent PTH or vehicle for 2 weeks using the same experimental design (number of mice/experimental group = 5-7). No improvement was observed after 2 weeks of intermittent PTH treatment in either WT or null animals (a-f). There was a genotype effect for BV/TV, Conn.D, SMI, and Tb.Th (a-c and e, respectively) consistent with the enhanced trabecular architecture of the null mice, regardless of treatment. g lCT images of vertebral trabecular bone from WT and Nmp4-KO mice that had been treated with intermittent PTH or vehicle for 7 weeks. Scale bar 1 mm. Data presented as average ± SD. P values were determined with a two-factor ANOVA. Tukey's HSD post hoc test was used to determine differences between the treatment groups if a significant genotype 9 treatment interaction was indicated b support the development of both cells. Animals were treated with intermittent PTH or vehicle for 2 or 3 weeks and RNA was harvested 1 h after the last injection. The AP-1 transcription factors c-fos and Fra-2 exhibited a significantly enhanced PTH-stimulated increase in Nmp4-KO mice (genotype 9 treatment interaction) after 2 weeks of treatment, but these differences were absent after 3 weeks of PTH (Table 6 ). Additionally, the transcription factor Nfatc1 was significantly elevated in the femur of null mice (genotype effect) at the 2-week time point but equivalent to the WT expression at 3 weeks of treatment (Table 6 ). We also examined the expression of several genes that mediate osteoblast-osteoclast signaling. Interestingly, the Nmp4-KO mice showed a significant increase in the expression of EphB4, the receptor for EphrinB2, its transmembrane ligand, which also showed an elevation in expression that approached significance; but again, these differences between the genotypes disappeared at the 3-week time point (Table 6 ). Both EphB4 and EphrinB2 were responsive to PTH in the null and WT mice (Table 6 ). Interestingly, the Rankl/Opg ratio was diminished in the null mice compared to WT animals at 2 and 3 weeks of treatment, which was significant at the later time point (Table 6) .
Further comparative analysis of femoral gene expression profiles between WT and null mice at the 2-week time period failed to show any significant differences between the two genotypes with one exception (Table 7 ). The expression of the prosurvival gene Bcl2 was not different in WT and null mice and did not respond to hormone in either genotype at this point in the treatment regimen; however, WT and Nmp4-KO mice were treated with intermittent PTH or vehicle (number of mice/experimental group = 6-7) for 2 weeks. A two-factor AVOVA was used to evaluate the individual parameters ), e Tb.Th (mm), and f Tb.Sp (mm) was compared between WT and Nmp4-KO mice that had been treated with intermittent PTH or vehicle for 7 weeks (number of mice/experimental group = 8). To evaluate the early hormone response, we compared bones from WT and Nmp4-KO mice that had been treated with intermittent PTH or vehicle for 2 weeks (number of mice/experimental group = 7-9). Both genotypes showed equal hormone-induced improvement of tibial a BV/TV, b Conn.D, c SMI, and e Tb.Th during the initial 2 weeks of treatment. There was a genotype effect for d Tb.N and f Tb.Sp, indicating enhanced aspects of tibial architecture in null mice at 12 weeks of age irrespective of treatment. g lCT images of tibial trabecular bone from WT and Nmp4-KO mice that had been treated with intermittent PTH or vehicle for 7 weeks. Scale bar 1 mm. P values were determined with a two-factor ANOVA. Tukey's HSD post hoc test was used to determine differences between the treatment groups if a significant genotype 9 treatment interaction was indicated the expression of Bax, the proapoptotic gene, was significantly attenuated in Nmp4-KO mice (Table 7) . M-csf, its receptor c-fms, and the osteoclast recruitment cytokine Mcp-1 showed no difference in their expression or PTH responsiveness between WT and Nmp4-KO animals ( Table 7) . Hormone induced over a 25-fold increase in Nurr1 expression in both WT and null mice ( Table 7) . The expression of Mkp-1, JunD, Smad3, and Lef1 was modestly but equally elevated with PTH in both genotypes (Table 7) . Conversely, the mRNA expression of the receptor for advanced glycation end products (Rage) was attenuated by hormone treatment in both WT and Nmp4-KO mice (Table 7) .
Next, we characterized the expression of genes that support bone formation by analyzing femoral RNA obtained 24 h after the last injection of intermittent PTH or vehicle after 2 weeks of treatment. We observed a treatment effect but no genotype effect or genotype 9 treatment interaction for Runx2, Osterix, Col1a1, Alpl, Mmp13, Sost, Bmp2, and Pthr1 mRNA profiles (Table 7) . Intermittent hormone treatment did not impact the expression of PTH-related peptide (Pthrp) in either genotype (Table 7) .
Our preliminary evaluation of gene expression in the tibia showed that the RNA profiles at 3 weeks of treatment were generally similar to those observed for the femur at the same time point with the exception of Nfatc1, which was still significantly elevated in the tibia of the null mice (Table 8) . Additionally, the decrease in the Rankl/Opg ratio did not reach significance in the tibia as demonstrated for the femur (Table 8) .
Discussion
The present data demonstrate that Nmp4/CIZ significantly blunts PTH-stimulated improvement in cancellous bone throughout the skeleton, that this repression of bone gain is apparent between 2 and 7 weeks of hormone treatment, and that Nmp4/CIZ suppresses osteoclast as well as osteoblast number and activity, likely by regulating key transcription factors critical to the development of both cells. The global impact of Nmp4 on the trabecular skeleton is in stark contrast to recent studies showing the site-specific effects of Rage [9] and connexin 43 [10] on PTH-induced cancellous bone improvement.
Nmp4/CIZ repression of the PTH-mediated increase in trabecular bone was not observed during the initial 2-week treatment period; WT and KO mice showed equivalent hormone-stimulated increases in BMD, BMC, trabecular improvement, and enhanced expression of numerous genes that support bone formation. At 7 weeks of hormone challenge the striking expansion of the null trabecular compartment had been added and bone histomorphometry indicated that both the KO and WT mice exhibited a diminished response to PTH, consistent with previous observations on C57BL/6 mice [17] . However, starting at 3 weeks of hormone challenge, the KO mice exhibited an enhanced and sustained PTH-induced increase in serum osteocalcin. The significance of the 2-to 3-week lag period required for distinguishing the difference in PTH-stimulated bone formation between the Nmp4-KO and WT mice remains to be elucidated. Does this delay represent the time necessary to dramatically expand the null bone-forming osteoblast population? Further histomorphometric analysis at various time points throughout the treatment regimen is required to address this question.
Of particular significance was our discovery of an osteoclast phenotype in the Nmp4-KO mouse. The null mice had significantly higher serum CTX; more osteoclasts were recovered from Nmp4-KO marrow cultures than from WT cultures, and the null osteoclasts were more active as determined by in vitro resorption of dentin. Interestingly, PTH had a more significant impact on decreasing the osteoclast-covered bone surface in null mice without significantly lowering serum CTX, perhaps in part a consequence of the enhanced activity of the null osteoclasts. Despite the multiple lines of evidence suggesting higher bone resorption in the untreated nulls, these mice Fig. 3 Number of mice/experimental group = 5-6). The parameters include mineral apposition rate (MAR), mineralizing surface/bone surface (MS/ BS), bone formation rate (BFR), the TRAP-stained surface to bone surface (TRAP ? S/BS), and the number of TRAP-stained cells on the bone surface (TRAP ? N/BS). A two-factor ANOVA was used to evaluate the impact of genotype and treatment on the individual parameter. A Tukey's HSD post hoc test was used to determine differences between treatment groups if a significant genotype 9 treatment interaction was indicated (TRAP ? S/BS). Groups not connected by the same letter are significantly different Fig. 4 PTH-treated Nmp4-KO mice exhibited strikingly distinct serum chemistries from WT animals. Whole blood was collected and serum separated from WT and Nmp4-KO mice treated with intermittent PTH or vehicle (number of mice/experimental group = 6-7) at baseline just prior to initiation of treatment, at 3 weeks of treatment, and at 7 weeks of treatment. a Raw longitudinal serum osteocalcin concentrations showed no genotype effect but revealed a significant treatment effect, a genotype 9 treatment interaction, and a genotype 9 time interaction, indicating that WT and null mice had equivalent baseline values but that Nmp4-KO had an enhanced response to hormone and a higher rate of increase over the experimental time period. b Percent change data confirmed the raw longitudinal data, revealing a significant genotype effect (higher rate of osteocalcin increase in nulls), a treatment effect, and a genotype 9 treatment interaction over the experimental period. c Raw longitudinal serum CTX concentrations showed a genotype effect but no significant treatment effect, no genotype 9 treatment interaction, and no genotype 9 time interaction. d Percent change CTX data showed no significant responsiveness to hormone treatment in WT and null mice. P values were determined with a repeatedmeasures MANOVA (longitudinal data) or a two-factor ANOVA are not osteopenic and in fact have a modestly enhanced skeleton, although the rate of bone accrual from 8 to 12 weeks is marginally slower in the null animals. Femoral bone marrow-derived osteoblasts from Nmp4/CIZ-deficient mice exhibited enhanced alkaline phosphatase expression and formed more mineralized nodules than WT osteoblasts [18] , suggesting in vivo that the null osteoblast outpaces the null osteoclast. Further study is required to determine if there is an increased rate of remodeling (activation frequency) with a positive bone balance in the untreated mice and if so, how this is achieved. Although the in vivo mRNA expression profiles represent a composite of multiple marrow and bone cell types, the transiently enhanced expression of c-fos, Fra-2, and Nfatc1 in the null mice may be part of the molecular mechanism contributing to the apparent increased number of osteoblasts and osteoclasts. Fra-2 plays a significant role in chondrocyte differentiation and matrix production in embryonic and newborn mice [19] and in regulating the size of osteoclasts [20] .
The contribution of c-Fos to the PTH anabolic response involves both osteoblasts and osteoclasts; in the former it is part of the immediate-early gene response [21] and, as such, is critical for subsequent induction of select target genes. As a key regulator of bone cell growth and differentiation, c-Fos often interacts with RUNX2 [22] . PTH stimulation of Mmp-13 transcription in osteoblast-like cells requires the cooperative interaction between the c-FosÁc-Jun AP-1 complex and RUNX2 [23] , and Nmp4/CIZ dampens this induction [8] . Consequently, the heightened PTH-stimulated increase in osteoblast c-Fos activity in Nmp4-KO mice may boost hormone transcriptional induction of some genes supporting the anabolic response. The impact of Nmp4/CIZ on c-fos and Fra-2 was specific within the context of the PTH-induced immediate-early response because we did not observe differences in other Number of mice/experimental group = 6-9 for 2 weeks or 6 for 3 weeks, harvested 1 h after the last injection. P values were determined with a two-factor ANOVA. A Tukey's HSD post hoc test was used to determine differences between treatment groups if a significant genotype 9 treatment interaction was indicated. Groups not connected by the same letter are significantly different aspects of this gene program including Nurr1, a transcription factor participating in PTH-mediated osteoblast gene induction [24] ; Mkp-1, a phosphatase implicated in PTH-mediated osteoblast cell cycle arrest [25] ; JunD, involved in osteoblast differentiation [26] ; or Smad3 and Lef1, trans-acting proteins involved in coupling the PTH and Wnt signaling pathways in osteoblasts [27] .
In addition to its role as a PTH-responsive osteoblast transcription factor, c-Fos is critical to osteoclastogenesis and plays a role in supporting the precursor cell's capacity to undergo differentiation [28] . It fulfills this role in part by mediating the induction of Nfatc1, another key transcription factor that supports osteoclastogenesis and osteoblast development [29] ; the elevation of c-fos mRNA expression P values were determined with a two-factor ANOVA. A Tukey's HSD post hoc test was used to determine differences between treatment groups if a significant genotype 9 treatment interaction was indicated. Groups not connected by the same letter are significantly different in the nulls may ultimately contribute to the enhanced Nfatc1 expression in these mice. Additionally, c-Fos has multiple and complex roles in regulating osteoblast-derived signals that regulate osteoclastogenesis and mature osteoclast activity including the RANKL/OPG signaling axis by governing the transcriptional activity of the Opg gene in the osteoblast and by activating RANKL target genes in osteoclasts; c-Fos also activates the IFN-c-driven RANKL negative feedback pathway in the osteoclast [30, 31] . The Rankl/Opg ratio was attenuated in the null mice, which achieved significance in the femur by 3 weeks of treatment; perhaps this ultimately contributed some protective effect from the enhanced osteoclast activity. Nmp4/CIZ had a negligible impact on the mRNA expression of other osteoclastogenic cytokines including Mcp-1, a cytokine involved in osteoclast recruitment [32] , as well as M-csf and its receptor c-fms, which activate the proliferation and survival of osteoclast precursors [33] . The significantly attenuated expression of the proapoptotic gene Bax in the null mice may contribute to a longer-lived osteoblast, critical to the PTH-induced anabolic mechanism [5] ; but further studies are required to confirm this possibility. Recent studies with c-fos-null animals indicate that interaction between immature osteoclasts and preosteoblasts may be necessary for an optimal response to intermittent PTH; specifically, the osteoclast precursors support the differentiation of preosteoblasts [34] [35] [36] [37] . In one potential scenario this coupling is mediated by the bidirectional interaction between an EphrinB2 ligand on the preosteoclast and the EphB4 receptor on the preosteoblast [34, 35] . Forward signaling from the osteoclast precursor to the preosteoblast enhances differentiation of the latter, whereas reverse signaling suppresses osteoclast differentiation [35] . Therefore, PTH appears to activate both forward and reverse EphrinB-EphB4 signaling, resulting in the enhancement of bone formation and the restraining of resorption [34] . This is consistent with the observed increased expression of EphB4 in Nmp4-KO mice and the marginally enhanced EphrinB2 expression in these animals. Future osteoblast-osteoclast coculture studies will be needed to investigate the potential impact of Nmp4/CIZ on the reciprocal regulation of these cells.
We propose that Nmp4/CIZ governs both the osteoblast and osteoclast cellular arms of the PTH-induced anabolic response by controlling the size, activity, and/or PTH responsiveness of these cell populations, in part via the modest suppression of several key transcription factors and receptors critical to the developmental and/or response pathways of both cells. The complex sequence of molecular and cellular events underlying Nmp4/CIZ regulation of bone remodeling remains to be elucidated. Nmp4/CIZ has been previously identified as an attractive potential therapeutic target for treating osteoporosis [38] , and the present finding that this protein regulates not only the osteoblast but also the osteoclast underscores this assertion.
